NX-2127

• CAT Number: I041300
• CAS Number: 2416131-46-7
• Molecular Formula: C39H45N9O5
• Molecular Weight: 719.83
• Purity: ≥95%
• Synonyms: 3-[4-[1-[[(3S)-1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]pyrrolidin-3-yl]methyl]piperidin-4-yl]anilino]-5-piperidin-1-ylpyrazine-2-carboxamide
• InChI: InChI=1S/C39H45N9O5/c40-35(50)34-36(43-32(21-41-34)46-15-2-1-3-16-46)42-27-6-4-25(5-7-27)26-13-17-45(18-14-26)22-24-12-19-47(23-24)28-8-9-29-30(20-28)39(53)48(38(29)52)31-10-11-33(49)44-37(31)51/h4-9,20-21,24,26,31H,1-3,10-19,22-23H2,(H2,40,50)(H,42,43)(H,44,49,51)/t24-,31?/m0/s1
• InChIKey: XLWJWCMQMBVNSG-ACXKHFGCSA-N
• SMILES: C1CCN(CC1)C2=CN=C(C(=N2)NC3=CC=C(C=C3)C4CCN(CC4)C[C@@H]5CCN(C5)C6=CC7=C(C=C6)C(=O)N(C7=O)C8CCC(=O)NC8=O)C(=O)N

NX-2127（Cat No.:I041300）is an investigational, small molecule inhibitor designed to target the protein degradation pathway, specifically focusing on the cereblon E3 ligase modulator mechanism. It is being explored in clinical trials for its potential in treating hematologic malignancies, such as multiple myeloma, by selectively degrading harmful proteins involved in tumor growth. NX-2127 works by inducing targeted protein degradation, leading to the elimination of oncogenic proteins that drive cancer cell survival. This novel therapeutic approach holds promise for improving cancer treatment outcomes, particularly in relapsed or refractory disease settings.